Abstract
Purpose
Continued tobacco smoking following a cancer diagnosis is associated with adverse outcomes. Our study aims to identify the demographic and clinical characteristics of survivors who quit smoking within a year of diagnosis.
Methods
We conducted a secondary analysis of the Measuring Your Health (MY-Health) study, a community-based survey cohort of 5506 cancer patients registered across four Surveillance, Epidemiology, and End Results (SEER) cancer registries. Using surveys completed 6–13 months after diagnosis, we identified 868 participants who reported smoking around the time of cancer diagnosis and compared their current smoking status. We employed logistic regression models to predict current smoking status, adjusting for clinical and demographic variables.
Results
The overall smoking cessation rate was 35% (n = 306). Survivors with non-small cell lung cancer were three times more likely to quit smoking compared to patients with non-smoking-related cancers (aOR = 3.23, 95% CI = 2.20–4.74). Participants with advanced stage cancer reported higher odds of quitting compared to those with localized cancer (aOR = 1.42, 95% CI = 1.02–1.96). Other characteristics that predicted quitting included being married, higher education level, and female sex (aOR = 2.01, 95% CI = 1.46–2.77; aOR = 1.74, 95% CI = 1.27–2.39; aOR = 1.54, 95% CI = 1.11–2.13, respectively).
Conclusions
This is one of the first studies to examine smoking cessation trends in a community-based, US cancer cohort during the year after diagnosis. Survivors with lung cancer and advanced cancer were significantly more likely to quit smoking.
Implications for Cancer Survivors
Practitioners may use this knowledge to target interventions and address substantial disparities in cessation rates among survivors with early stage and non-lung cancers.
Similar content being viewed by others
References
US Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2019;www.cdc.gov/cancer/dataviz.
Henley SJ, Thomas CC, Sharapova SR, Momin B, Massetti GM, Winn DM, et al. Vital signs: disparities in tobacco-related cancer incidence and mortality - United States, 2004-2013. MMWR Morb. Mortal. Wkly Rep. 2016;65:1212–8.
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
Romaszko-Wojtowicz A, Buciński A, Doboszyńska A. Impact of smoking on multiple primary cancers survival: a retrospective analysis. Clin Exp Med, Springer International Publishing. 2018;18:391–7.
Florou AN, Gkiozos IC, Tsagouli SK, Souliotis KN, Syrigos KN. Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir. Care. 2014;59:1924–36.
Zevallos JP, Mallen MJ, Lam CY, Karam-Hage M, Blalock J, Wetter DW, et al. Complications of radiotherapy in laryngopharyngeal cancer: effects of a prospective smoking cessation program. Cancer. 2009;115:4636–44.
Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. CHEST. 2004;126:1733–41.
O’Malley M, King AN, Conte M, Ellingrod VL, Ramnath N. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J. Thorac. Oncol. 2014;9:917–26.
Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 2006;12:2166–71.
van der Bol JM, Mathijssen RHJ, Loos WJ, Friberg LE, van Schaik RHN, de Jonge MJA, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 2007;25:2719–26.
Platek AJ, Jayaprakash V, Merzianu M, Platek ME, Cohan DM, Hicks WL Jr, et al. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation. Laryngoscope. 2016;126:2733–8.
Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, et al. Smoking cessation, version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2016:1430–68.
Hanna N. Helping patients quit tobacco: ASCO’s efforts to help oncology care specialists. J Oncol Pract. 2013;9:263–4.
Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. AACR Subcommittee on Tobacco and Cancer. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin. Cancer Res. 2013;19:1941–8.
Peters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, et al. Tobacco assessment in actively accruing national cancer institute cooperative group program clinical trials. J. Clin. Oncol. 2012;30:2869–75.
Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J. Thorac. Oncol. 2013;8:543–8.
Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, et al. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract. 2013;9:258–62.
Gallaway MS, Glover-Kudon R, Momin B, Puckett M, Lunsford NB, Ragan KR, et al. Smoking cessation attitudes and practices among cancer survivors–United States, 2015. J. Cancer Surviv. 2019:1–9.
Goldstein AO, Ripley-Moffitt CE, Pathman DE, Patsakham KM. Tobacco use treatment at the US National Cancer Institute’s designated Cancer Centers. Nicotine Tob. Res. 2013;15:52–8.
Cooley ME, Poghosyan H, Sprunck-Harrild K, Winickoff JP, Edge SB, Emmons KM. Tobacco treatment implementation within 28 commission on cancer accredited programs in the Northeast region of the USA: a pilot study. In: Translational Behavioral Medicine, vol. 8. 1st ed; 2018. p. 706–13.
Burcu M, Steinberger EK, Sorkin JD. Health care access and smoking cessation among cancer survivors: implications for the Affordable Care Act and survivorship care. J. Cancer Surviv. 2015;10:1–10.
Gallaway MS. Smoking and smoking cessation among persons with tobacco- and non-tobacco-associated cancers. J Commun Health, Springer US. 2019;44:552–60.
Antwi GO, Lohrmann DK, Jayawardene W, Chow A, Obeng CS, Sayegh AM. Associations between e-cigarette and combustible cigarette use among U.S. cancer survivors: implications for research and practice. J. Cancer Surviv. 2019:1–10.
Little MA, Klesges RC, Bursac Z, Halbert JP, Ebbert J, Talcott GW, et al. Correlates of smoking status in cancer survivors. J. Cancer Surviv. 2018:1–7.
Marcus JL, Katz KA, Krakower DS, Calabrese SK. Risk compensation and clinical decision making—the case of HIV preexposure prophylaxis. N. Engl. J. Med. 2019;380:510–2.
D’Angelo H, Rolland B, Adsit R, Baker TB, Rosenblum M, Pauk D, et al. Tobacco treatment program implementation at NCI cancer centers: progress of the NCI Cancer Moonshot-Funded Cancer Center Cessation Initiative. Cancer Prev Res, American Association for Cancer Research. 2019;12:735–40.
Westmaas JL, Newton CC, Stevens VL, Flanders WD, Gapstur SM, Jacobs EJ. Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J. Clin. Oncol. 2015;33:1647–52.
Robinson CD, Gonzalez-Feliciano A, Mucci LA, Markt SC. Smoking cessation among men following cancer diagnosis: a matched cohort study. J. Cancer Surviv. 2018:1–8.
Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J. Clin. Oncol. 2005;23:5814–30.
Gritz ER, Fingeret MC, Vidrine DJ, Lazev AB, Mehta NV, Reece GP. Successes and failures of the teachable moment. Cancer. 2006;106:17–27.
Frazelle ML, Friend PJ. Optimizing the teachable moment for health promotion for cancer survivors and their families. JADPRO. 2016;7.
Tseng T-S, Lin H-Y, Martin MY, Chen T, Partridge EE. Disparities in smoking and cessation status among cancer survivors and non-cancer individuals: a population-based study from National Health and Nutrition Examination Survey. J. Cancer Surviv. 2010;4:313–21.
Tseng T-S, Lin H-Y, Moody-Thomas S, Martin M, Chen T. Who tended to continue smoking after cancer diagnosis: the national health and nutrition examination survey 1999-2008. BMC Public Health. 2012;12:784.
Berg CJ, Thomas AN, Mertens AC, Schauer GL, Pinsker EA, Ahluwalia JS, et al. Correlates of continued smoking versus cessation among survivors of smoking-related cancers. Psycho-Oncology. 2012;22:799–806.
Gritz ER, Talluri R, Fokom Domgue J, Tami-Maury I, Shete S. Smoking behaviors in survivors of smoking-related and non–smoking-related cancers. JAMA Netw. Open. 2020;3:e209072–16.
Swoboda CM, Walker DM, Huerta TR. Likelihood of smoking among cancer survivors: an updated health information national trends survey analysis. Nicotine Tob. Res. 2019;21:1636–43.
Paul CL, Tzelepis F, Boyes AW, D’Este C, Sherwood E, Girgis A. Continued smoking after a cancer diagnosis: a longitudinal study of intentions and attempts to quit. J. Cancer Surviv. 2019:1–8.
Bryant J, Boyes AW, Hall A, Girgis A, D’Este C, Sitas F. Prevalence and factors related to smoking and smoking cessation 6 months following a cancer diagnosis: a population-based study. J. Cancer Surviv. 2016:1–9.
Martínez Ú, Brandon TH, Sutton SK, Simmons VN. Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psycho-Oncology. 2018;27:2104–10.
Jensen RE, Moinpour CM, Keegan THM, Cress RD, Wu X-C, Paddock LE, et al. The Measuring Your Health study: leveraging community-based cancer registry recruitment to establish a large, diverse cohort of cancer survivors for analyses of measurement equivalence and validity of the Patient Reported Outcomes Measurement Information System® (PROMIS®) short form items. Psychol. Test Assess. Model. 2016;58:99–117.
Jensen RE, Moinpour CM, Potosky AL, Lobo T, Hahn EA, Hays RD, et al. Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort. Cancer. 2nd ed. 2016;123:327–35.
Underwood JM, Townsend JS, Tai E, White A, Davis SP, Fairley TL. Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J. Cancer Surviv. 2012;6:333–44.
Mayer DK, Carlson J. Smoking patterns in cancer survivors. Nicotine Tob. Res. 2010;13:34–40.
Hall DL, Neil JM, Ostroff JS, Hawari S, O’Cleirigh C, Park ER. Perceived cancer-related benefits of quitting smoking and associations with quit intentions among recently diagnosed cancer patients. J. Health Psychol. 2019:1359105319845131.
Coups EJ, Dhingra LK, Heckman CJ, Manne SL. Receipt of provider advice for smoking cessation and use of smoking cessation treatments among cancer survivors. J. Gen. Intern. Med. 2009;24(Suppl 2):S480–6.
Sterba KR, Garrett-Mayer E, Carpenter MJ, Tooze JA, Hatcher JL, Sullivan C, et al. Smoking status and symptom burden in surgical head and neck cancer patients. Laryngoscope, Wiley. 2016;127:127–33.
Choi SH, Terrell JE, Bradford CR, Ghanem T, Spector ME, Wolf GT, et al. Does quitting smoking make a difference among newly diagnosed head and neck cancer patients? Nicotine Tob. Res. 2016;18:2216–24.
Warren GW, Arnold SM, Valentino JP, Gal TJ, Hyland AJ, Singh AK, et al. Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother. Oncol. 2012;103:45–8.
Morales NA, Romano MA, Michael Cummings K, Marshall JR, Hyland AJ, Hutson A, et al. Accuracy of self-reported tobacco use in newly diagnosed cancer patients. Cancer Causes Contr. Springer Netherlands. 2013;24:1223–30.
Waggoner SE, Darcy KM, Fuhrman B, Parham G, Lucci J, Monk BJ, et al. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol. Oncol. 2006;103:853–8.
Acknowledgements
We thank Arnold L. Potosky, PhD for his input on prior drafts of this manuscript.
Funding
Research reported in this publication was supported by the National Institutes of Health under award number U01AR057971 (principal investigators: Arnold Potosky and Carol Moinpour) and by the National Cancer Institute under award number P30CA051008.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Disclaimer
The article was prepared as part of one of the author’s (REJ) official duties as employees of the US Federal Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Cancer Institute.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gummerson, S.P., Lowe, J.T., Taylor, K.L. et al. The characteristics of patients who quit smoking in the year following a cancer diagnosis. J Cancer Surviv 16, 111–118 (2022). https://doi.org/10.1007/s11764-021-01009-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-021-01009-7